C4 Therapeutics, Inc. (CCCC)

In the past six months, C4 Therapeutics reported its Q4 and full-year 2025 financial results, with a revenue of $11.0 million for Q4 and $35.9 million for the full year, and a net loss of $105.0 million. The company announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) and the first patient dosed in a Phase 1b trial of Cemsidomide in combination with Elranatamab for relapsed/refractory multiple myeloma. Analysts have given C4 Therapeutics a consensus rating of "Moderate Buy" with an average 12-month target price of $7.75. The stock has traded between $3.82 and $1.08, with a closing price of $2.41 as of March 27, 2026, and a market capitalization of $262.49 million as of March 25, 2026.

Information detailing demand seasonality for C4 Therapeutics' products is not readily available, which is typical for a clinical-stage biopharmaceutical company. The demand for its product candidates is driven by their progression through clinical trials and potential future market approval, rather than seasonal consumer patterns. Historically, December has been the strongest month for C4 Therapeutics, Inc. stock, with an average return of 30.89%, while March has tended to be the weakest, averaging -21.15% return.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines through targeted protein degradation science. The company is in the Biotechnology industry and utilizes its TORPEDO platform to design small-molecule medicines for difficult-to-treat diseases. Its major product candidates include Cemsidomide, CFT1946, and CFT8919, which are in clinical development for multiple myeloma, non-Hodgkin lymphoma, BRAF V600E-mutated solid tumors, and non-small cell lung cancer, respectively. The company has strategic collaborations with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGaA.

C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States.

C4 Therapeutics is recognized for its focus on targeted protein degradation science and its innovative approach to developing new medicines. Positive developments in clinical trials and strategic collaborations enhance its standing. However, the company faces risks associated with drug development and financial performance, which can influence perception. Analyst ratings currently lean towards a "Moderate Buy."

C4 Therapeutics has significant institutional ownership, with 116 institutional owners and shareholders holding 80,167,753 shares, representing approximately 81.82% of the company. Major institutional owners include Point72 Asset Management, L.P., Morgan Stanley, and Ra Capital Management, L.p. Key individual owners include Marc A. Cohen, who owns 8.31 million shares representing 8.52% of the company, and Alain J. Cohen.